norepinephrine Bitartrate recall — Class II (D-0438-2026) · pharmaranks
Class IIOngoing
norepinephrine Bitartrate recall
FDA recall D-0438-2026 · initiated Mar 20, 2026
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Details
Product
norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5026-02
Recalling company
Fagron Compounding Services
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the U.S.A.
Initiated
Mar 20, 2026
FDA report date
Apr 15, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.